Multiresistant tuberculosis;LES TUBERCULOSES MULTIRESISTANTES

Presse Medicale

Volumn 25, Issue 8, 1996, Pages 393-398

  Bouvet, E ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHIONAMIDE; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TUBERCULOSTATIC AGENT; VIOMYCIN;

DRUG EFFICACY; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; REVIEW; TUBERCULOSIS; UNITED STATES; DRUG COMBINATION; PROGNOSIS;

ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; FRANCE; HUMANS; PROGNOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0029892235     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. CDC. Nosocomial transmission of multidrug-resistant tuberculosis among hiv-infected persons - Florida and New York, 1088-1991. MMWR 1991; 40:585-91.
2. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW The emergence of drug-resistant tuberculosis in New York City N Engl J Med 1993; 328:521-6
3. Jarvis WR, CDC. Multidrug resistant tuberculosis (MDR-TB) outbreaks and follow up studies. II° National american conference on retroviral infections. Washington; January 1995.
4. Fridkin SK, Managan L, Bolyard E, Mayhall GC, Jarvis WR, CDC. Atlanta, Society for hospital epidemiology of America (SHEA). Efficacy of tuberculosis (TB) infection control (IC) measures in US hospitals environmental and respiratory protective devices. Abstracts of the 34th ICAAC, Orlando, Oct 1994, J176: 186.
5. Gordin D, Nelson E, Matts J, Cohn D, El Sadr A The impact of human immunodeficiency virus (HIV) infection on drug-resistant tuberculosis (TB) in the United states (US). Abstracts of the 35th ICAAC. Sept 1995. San Francisco. 182:219
6. Grosset J, Truffot-Pernot C, Schwoebel V, Declut D, Haeghebaert S. Évolution de la résistance de Mycobacterium tuberculosis aux antibiotiques. In . Prévention des infections nosocomiales, Arnette Blackwell, Paris, 1995 : 215-27.
7. British Thoracic Society. A controlled trial of 6 months chemotherapy in pulmonary turberculosis. Final report : results during the 36 months after the end of chemotherapy and beyond Br J Dis Chest 1984; 78:330-6.
8. Bouvet E, Desenclos JC. Recommandations pour la prévention de la tuberculose dans les lieux de soins BEH 1992; 53:251-2.
9. Conférence d'Experts sur la Tuberculose, 15 décembre 1994, Paris La tuberculose en France: comment arrêter l'épidémie actuelle. Med Mal Infect 1995; 25:454-78.
10. Bloch AB, Cauthen GM, Onorato IM et al Nationwide survey of drug-resistant tubercolusis in the united states. JAMA 1994; 271:665-71.
11. Decludt B, Schwoebel V, Haeghebaert S et al. Surveillance de la tuberculose à bacilles multirésistants en 1993 BEH 1994, 50 235-6.
12. Schwoebel V. Épidémiologie de la tuberculose multirésistante en France (1992-1993). Med Mal Infect 1995; 25:362-8.
13. Bouvet E, Casalino E, Mendoza-Sassi G et al Nosocomial outbreak of multidrug resistant Mycobacterium bovis among HIV infected patients. A case-control study. AIDS 1993; 7:1453-60.
14. Warburton ARE, Jenkins PA, Waight PA, Watson JM Drug resistance in initial isolates of Mycobacterium tuberculosis in England and Wales, 1982-1991. CDR Review 1993; 3(13):175-8.
15. Tahaoglu K, Kizkin O, Karagoz T, Tor M, Partal M, Sadoglu T. High initial and acquired drug resistance in pulmonary tuberculosis in Turkey. Tubercle Lung Dis 1994; 75:324-8.
16. Telzak EE, Sepkowitz K, Alpert P et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333:907-11
17. Salomon N, Turett G Washington, II° Conférence Nationale Américaine sur les Infections liées aux rétrovirus Février 1995.
18. Mitchinson DA, Nunn AJ Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133:423-30.
19. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328:527-32.
20. Weiss SE, Slocum PC, Blais FX et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994, 330 1179-84.
21. Senneville E. Traitement des patients porteurs de souches résistantes. Med Mal Infect 1995; 25:369-76.
22. Kohno S, Koga H, Kaku M, Maesaki S, Hara K. Prospective comparative study of ofloxacine or ethambutol for the treatment of pulmonary tuberculosis. Chest 1992, 102:1815-18
23. Iseman MD. Treatment of multi-drug resistant tuberculosis. N Engl J Med 1993, 329:784-91.
24. Direction Générale de la Santé Perronne C, Vincent V. Diagnostic et traitement de la tuberculose. Guide à l'usage des praticients. Juillet 1994.
25. Tattevin P, Cremieux AC, Bouvet E, Carbon C. La tuberculose. Actualités thérapeutiques. Presse Med (sous presse)